Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 12 of 116

  1. Fianlimab

    Regeneron UK Limited

    Melanoma

    phase 3 small molecule active

    3 trials

  2. Ficerafusp alfa

    Bicara Therapeutics

    Metastatic Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  3. Firmonertinib

    ArriVent BioPharma

    Non-Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. Fluzoparib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Metastatic

    phase 3 small molecule active

    2 trials

  5. ForeCYTE Breast Aspirator

    ATOSSA THERAPEUTICS, INC.

    Breast Cancer, Preneoplastic Conditions, BRCA

    phase 3 other terminated

    1 trial

  6. Fulvestrant

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  7. Fulvestrant

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  8. Fulvestrant combined with Pyrotinib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Breast Cancer

    phase 3 small molecule active

    1 trial

  9. Futibatinib, FULVESTRANT

    Taiho Pharma Netherlands B.V.

    Malignant Solid Tumors

    phase 3 small molecule active

    1 trial

  10. GALLIUM (68GA) CHLORIDE, TILMANOCEPT

    Disc Medicine

    Carcinoma of the parotid gland

    phase 3 small molecule active

    1 trial

  11. GALLIUM (68GA) CHLORIDE, TILMANOCEPT

    Disc Medicine

    Endometrial cancer, uterine cancer

    phase 3 small molecule active

    1 trial

  12. GCAR-7213

    Adaptive Biotechnologies Corp

    Oncology - Glioblastoma (GBM)

    phase 3 small molecule active

    1 trial

  13. GCO-003 TARLANEC

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)

    phase 3 small molecule active

    1 trial

  14. GCT1046-06

    Genmab A/S

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. GCT1184-02

    Genmab A/S

    Platinum-resistant Ovarian Cancer

    phase 3 small molecule active

    1 trial

  16. GCT1184-03

    Genmab A/S

    Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer

    phase 3 small molecule active

    1 trial

  17. GCT3013-05

    Genmab A/S

    B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  18. GEICAM/2011-03_S1007

    Ningbo Cancer Hospital

    patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®

    phase 3 small molecule active

    1 trial

  19. GEMCITABINE for Patients with histologically or…

    AstraZeneca AB

    Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder

    phase 3 small molecule active

    1 trial

  20. GIMEMA AML1919

    Fondazione Telethon ETS

    Acute Myeloid Leukemia (LMA) with FLT3 mutation

    phase 3 small molecule active

    1 trial

  21. GLUCOPHAGE 500 mg tabletki powlekane, Placebo

    Bial Portela & Companhia S.A.

    papillary thyroid carcinoma

    phase 3 small molecule active

    1 trial

  22. GO29431

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  23. GO29527

    Hoffmann-La Roche

    Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. GO39942

    Hoffmann-La Roche

    Previously Untreated Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  25. GO40241

    Hoffmann-La Roche

    Early-Stage Resectable Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  26. GO41717

    Hoffmann-La Roche

    Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  27. GO41767

    Hoffmann-La Roche

    Small cell lung cancer (SCLC)

    phase 3 small molecule active

    1 trial

  28. GO41854

    Hoffmann-La Roche

    Non−small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  29. GO41944

    Hoffmann-La Roche

    Relapsed or refractory diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  30. GO42909

    Hoffmann-La Roche

    Relapsed/refractory follicular lymphoma

    phase 3 other active

    1 trial

  31. GO43104

    Hoffmann-La Roche

    Small-Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  32. GO45006

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  33. GS-US-577-6153

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  34. GS-US-592-6173

    Gilead Sciences Pty Limited

    PD-L1 Positive Metastatic Triple-Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  35. GS-US-592-6238

    Gilead Sciences Pty Limited

    PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting

    phase 3 small molecule active

    1 trial

  36. GS-US-595-6184

    Gilead Sciences Pty Limited

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  37. GS-US-600-6165

    Gilead Sciences Pty Limited

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  38. GS-US-626-6216

    Gilead Sciences Pty Limited

    Metastatic Non–Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  39. GS-US-682-6769

    Gilead Sciences Pty Limited

    Recurrent or Persistent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  40. GSK 2132231A

    GlaxoSmithKline

    Melanoma

    phase 3 small molecule terminated

    1 trial

  41. GSK2118436

    GlaxoSmithKline

    Cancer

    phase 3 small molecule completed

    1 trial

  42. Ga-68-PSMA-11

    Telix Innovations

    Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  43. Gefitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  44. Gefitinib

    AstraZeneca

    Non-Small-Cell Lung Carcinoma

    phase 3 small molecule completed

    1 trial

  45. Gemcitabine

    AstraZeneca

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  46. Gemcitabine,Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  47. General anesthesia and opioids

    Elan Pharma International

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  48. Gilteritinib

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.